SG/CALL/ELI LILLY & CO/1000/0.1/21.06.24 | Real-time Boerse Frankfurt Warrants 07:14:51 13/05/2024 pm IST | ||
| 0.001 EUR | -88.89% |
|
| Current month | -95.26% | ||
| 1 month | -98.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/24/13 | 0.001 | -88.89% | 0 |
| 10/24/10 | 0.009 | -78.57% | 0 |
| 09/24/09 | 0.042 | -8.70% | 0 |
| 08/24/08 | 0.046 | -19.30% | 0 |
| 07/24/07 | 0.057 | +46.15% | 0 |
Real-time Boerse Frankfurt Warrants
Last update May 13, 2024 at 07:14 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU997G |
| ISIN | DE000SU997G9 |
| Date issued | 05/03/2024 |
| Strike | 1,000 $ |
| Maturity | 21/06/2024 (39 Days) |
| Parity | 10 : 1 |
| Emission price | 1.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.21 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.139 € |
| Spread % | 99.29% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
760
USD
Average target price
850.4
USD
Spread / Average Target
+11.90%
- Stock Market
- Warrants
- Warrant
